Patents Examined by Michael D. Pak
  • Patent number: 10407481
    Abstract: The present invention provides fusion polypeptides comprising polypeptide ligands that are modified by circular permutation and fused to at least one polypeptide fusion partner wherein such fusion polypeptides have new, improved or enhanced biological functions or activities. Such improvements include, but are not limited to, increased binding affinity, increased activity, increased agonist activity (super agonist), antagonist activity, increased accessibility, increased flexibility of the active site, increased stability, broader and/or changed substrate specificity, and combinations thereof.
    Type: Grant
    Filed: July 25, 2016
    Date of Patent: September 10, 2019
    Assignee: Alkermes Pharma Ireland Limited
    Inventor: Juan Alvarez
  • Patent number: 10369191
    Abstract: Stress, such as from physical, metabolic or psychological trauma, is associated with enduring secondary complications leading to morbidity and/or death in subjects that receive the stress insult. The epigenetic oxidative stress response to a stress insult is characterized by (a) global epigenetic events such as changes in DNA methylation and phosphorylation of Ser10 and acetylation of Lys9/14 residues of histone-3 (b) significant systemic elevations in analytes of oxidative stress in body fluids such as blood or urine and (c) deterioration of clinically relevant parameters such as glycemic control, organ function, lean body mass and rate of healing. The applicant teaches a method of counteracting the grave systemic effects of stress insult with reference to the epigenetic oxidative stress response, by daily subcutaneous bolus injections of nephrilin peptide beginning soon after insult and continuing for seven days.
    Type: Grant
    Filed: September 16, 2016
    Date of Patent: August 6, 2019
    Inventor: Desmond D. Mascarenhas
  • Patent number: 10364350
    Abstract: Disclosed is a vesicular system comprising a surface with a vesicle immobilized thereon. The immobilized vesicle has a circumferential membrane of an amphiphilic polymer. The vesicle is coupled to a surface by means of a molecule with a non-polar moiety. The non-polar moiety comprises a main chain of 3 to about 30 carbon atoms and 0 to about 12 heteroatoms selected from Si, O, S, and Se. The molecule with the non-polar moiety is coupled to the surface via a covalent or non-covalent bond. A portion of the non-polar moiety is integrated in the circumferential membrane.
    Type: Grant
    Filed: April 20, 2010
    Date of Patent: July 30, 2019
    Inventors: Madhavan Nallani, Eva-Kathrin Sinner, Madanagopal Kunnavakkam
  • Patent number: 10329355
    Abstract: The present invention provides compositions and methods for treating cancer in a human. The invention relates to targeting the stromal cell population in a tumor microenvironment. For example, in one embodiment, the invention provides a composition that is targeted to fibroblast activation protein (FAP). The invention includes a chimeric antigen receptor (CAR) which comprises an anti-FAP domain, a transmembrane domain, and a CD3zeta signaling domain.
    Type: Grant
    Filed: May 19, 2016
    Date of Patent: June 25, 2019
    Assignees: The Trustees of the University of Pennsylvania, The Wistar Institute of Anatomy and Biology
    Inventors: Carl H. June, Ellen Pure, Liang-Chuan Wang, Steven Albelda, John Scholler
  • Patent number: 10324099
    Abstract: Provided herein are novel assays for the measurement of androgens such as testosterone in a sample. The assays utilize sensitive androgen receptor mutants and have much greater sensitivity than assays based on wild-type androgen receptors. The assays of the invention can detect androgens at concentrations as low as 1 ng/dl in serum, urine, environmental samples and other samples. The invention encompasses novel assay methods as well as nucleic acid sequences, proteins, and cells. Advantageously, the assays provide a measure of physiologically relevant androgen concentrations in a sample, taking into account the presence of androgen-binding factors or anti-androgen drugs in serum.
    Type: Grant
    Filed: March 24, 2015
    Date of Patent: June 18, 2019
    Assignee: The Regents of the University of California
    Inventor: Fred Schaufele
  • Patent number: 10324095
    Abstract: A method of predicting the risk of developing osteoarthritis (OA) comprising: (a) measuring the nuclear cellular level of prohibitin (PHB-1) in nucleated cells present in a blood sample from a subject having or suspected of having OA; and (b) comparing said nuclear cellular level to that corresponding to a control sample; and (c) identifying the subject as being at risk of developing OA when the nuclear cellular level of said PHB-1 in said blood sample is higher than in the control sample; and a composition for determining the risk of developing osteoarthritis (OA), said composition comprising: a cell sample from a subject; and a non-naturally occurring molecule for detecting nuclear accumulation of PHB1.
    Type: Grant
    Filed: May 19, 2016
    Date of Patent: June 18, 2019
    Inventor: Alain Moreau
  • Patent number: 10308717
    Abstract: The invention provides compositions and methods for treating diseases associated with expression of EGFRvIII. The invention also relates to chimeric antigen receptor (CAR) specific to EGFRvIII, vectors encoding the same, and recombinant T cells comprising the anti-EGFRvIII CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises an anti-EGFRvIII binding domain.
    Type: Grant
    Filed: June 15, 2016
    Date of Patent: June 4, 2019
    Assignees: Novartis AG, The Trustees of the University of Pennsylvania, University of Pittsburgh—of The Commonwealth System of Higher Education
    Inventors: Jennifer Brogdon, Laura Alexandra Johnson, Carl H. June, Andreas Loew, Marcela Maus, John Scholler, Hideho Okada
  • Patent number: 10308709
    Abstract: Disclosed herein are antibodies and methods of using said antibodies to detect Golgi protein 73 (GP73) and fucosylated GP73 in a sample.
    Type: Grant
    Filed: October 11, 2016
    Date of Patent: June 4, 2019
    Assignee: Abbott Laboratories
    Inventors: Bailin Tu, Robert N. Ziemann, Bryan C. Tieman, Philip M. Hemken, Carol S. Ramsay, Carolyn J. Strobel, David J. Hawksworth, Larry G. Birkenmeyer, Cheng Zhao, Susan E. Brophy, Barry L. Dowell, Anthony S. Muerhoff
  • Patent number: 10301383
    Abstract: Isolated antibodies that specifically bind to an epitope comprised in the stretch of amino acids ranging from amino acid 76 to amino acid 84 of human insulin-like growth factor-1 precursor (SEQ ID NO:1). Use of the novel antibodies for the sensitive and specific detection of insulin-like growth factor-1, in some embodiments while in the presence of high excess concentration of insulin-like growth factor-2, for example in a bodily fluid sample.
    Type: Grant
    Filed: January 22, 2016
    Date of Patent: May 28, 2019
    Assignee: Roche Diagnostics Operations, Inc.
    Inventors: Herbert Andres, Hartmut Duefel, Michael Gerg, Frank Kowalewsky, Christian Scholz, Michael Schraemi
  • Patent number: 10301365
    Abstract: The present invention provides isolated Met e 1 polypeptides and nucleic acids encoding the isolated polypeptides that can prevent and/or alleviate an allergic response to shellfish tropomyosin. The polypeptides are based on the shrimp tropomyosin Met e 1 protein and have been modified to act as hypoallergens. The Met e 1 hypoallergens have low to no IgE reactivity or allergenicity and are useful for prophylactic and/or therapeutic treatment of shellfish allergy in subject in need thereof.
    Type: Grant
    Filed: October 3, 2016
    Date of Patent: May 28, 2019
    Assignees: The Chinese University of Hong Kong, The Regents of the University of California
    Inventors: Ka Hou Chu, Patrick S. C. Leung, Yee Yan Christine Wai, Yat Hin Nicki Leung
  • Patent number: 10294296
    Abstract: Administration of a mAb that specifically binds IL-1? is useful for treating tumor-associated diseases in human subjects.
    Type: Grant
    Filed: August 23, 2011
    Date of Patent: May 21, 2019
    Assignee: XBiotech, Inc.
    Inventor: John Simard
  • Patent number: 10233249
    Abstract: Provided herein in certain embodiments are antibodies, antibody fragments, pharmaceutical compositions, methods for modulating the functions of estrogen receptor alpha 36, and methods for preventing and/or treating diseases mediated by estrogen receptor alpha 36.
    Type: Grant
    Filed: March 19, 2014
    Date of Patent: March 19, 2019
    Inventors: Xueming Qian, Kun Meng, Feng Chen, Xiao Shang, Jing Wang, Lu Li, Congya Zhou
  • Patent number: 10221231
    Abstract: The present invention relates to fusion proteins for the expression of G-protein coupled receptor proteins (GPCR) with the fusion partners, as inserted fragments, from mammalian cells. The fusion partners are from a fragment of APJ protein (“the APJ protein fragment”) or a fragment with homology of more than 90% similarity to the APJ protein fragment; or a fragment of RGS16 protein (the “RGS16 protein fragment”) or a fragment with homology of more than 90% similarity to the RGS16 protein fragment; or the fragment of DNJ protein (the “DNJ protein fragment”) or a fragment with homology of more than 90% similarity to DNJ protein fragment. The fusion expression of GPCR with the above mentioned fusion partners can improve the protein yield and stability when purified from cells. Therefore, these fusion protein partners can be widely used for the study of GPCR proteins.
    Type: Grant
    Filed: April 24, 2017
    Date of Patent: March 5, 2019
    Inventors: Jianhua Cai, Jian Shen, Fan Jiang, Na Li, Wentao Wei, Xiuhong Zeng, Xiaoyan Su, Min Han, Delin Ren, Chen Mao
  • Patent number: 10221239
    Abstract: The present invention relates to methods for treating ischemic stroke including extension of the therapeutic time window for reperfusion. More particularly, the invention relates to a method of treating stroke in a subject by inhibiting the transient receptor potential melastatin 4 (TRPM4) channel. The present invention also provides uses of TRPM4 inhibitors, TRPM4 antibodies and kits for use in the methods of the invention.
    Type: Grant
    Filed: June 30, 2014
    Date of Patent: March 5, 2019
    Inventors: Ping Liao, Kok Poh Loh
  • Patent number: 10206911
    Abstract: The present invention encompasses the recognition that an F876L mutation of the androgen receptor (AR) gene confers resistance to the antiandrogens enzalutamide (MDV3100) and ARN-509 and is associated with incidence and/or risk of castration resistant prostate cancer (CRPC). The present invention also provides other AR polypeptide sequences associated with increased incidence and/or risk of CRPC. The present invention also provides screening methods for identification and/or characterization of novel AR polypeptide sequences associated with increased incidence and/or risk of CRPC via exposure to antiandrogens and for identification and/or characterization of agents to treat and/or reduce risk of CRPC by virtue of their effect on AR transcriptional activation.
    Type: Grant
    Filed: October 25, 2013
    Date of Patent: February 19, 2019
    Assignee: Memorial Sloan-Kettering Cancer Center
    Inventors: Minna D. Balbas, Charles L. Sawyers, Philip Watson
  • Patent number: 10184112
    Abstract: Disclosed are: a culture medium containing a specific growth factor and at least one phospholipid; a composition for preparation of the culture medium; a kit; and a method. A technique can be provided which uses a serum-free or low-serum culture medium and has a promoting effect on the proliferation of an animal cell comparable to the promoting effect obtained by the culture in a serum-containing culture medium.
    Type: Grant
    Filed: May 29, 2015
    Date of Patent: January 22, 2019
    Assignee: Two Cells Co., Ltd.
    Inventors: Yukio Kato, Jin Chang Shao, Yuki Katsura, Koichiro Tsuji
  • Patent number: 10156557
    Abstract: The invention provides calcium-binding photoproteins which can detect light emission with a higher sensitivity. The proteins of the invention comprising the amino acid sequence of SEQ ID NO: 2 can be used for the detection and measurement of calcium ions. The proteins of the invention are useful as reporter proteins, luminescent markers, etc. The polynucleotides of the invention are useful as reporter genes, etc.
    Type: Grant
    Filed: May 30, 2014
    Date of Patent: December 18, 2018
    Inventors: Satoshi Inouye, Yuiko Sahara
  • Patent number: 9974842
    Abstract: Antibodies binding to sites on the alpha-subunit of the (Na++K+)-ATPase increase cardiac contraction of both ventricular myocytes and mouse heart. In particular, antibodies binding to the RSATEEEPPNDD (SEQ ID NO: 1) or DVEDSYGQQTYEQR (SEQ ID NO: 2) peptides (or isoforms/derivatives thereof) of the alpha-subunit of the (Na++K+)-ATPase, have been found to be highly inotropic. Both the antibodies and the peptides are important for the treatment of human heart failure and other contractile disorders.
    Type: Grant
    Filed: March 7, 2016
    Date of Patent: May 22, 2018
    Inventor: Kai Yuan Xu
  • Patent number: 9958462
    Abstract: This invention relates to a simple end point assay for detection of transient intracellular Ca2+ with broad applicability to many Ca2+ channel proteins comprising, Generation of expression constructs for the fusion proteins having the Ca2+/calmodulin dependent protein kinase II (CaMKII) phosphorylation sites of NR2A or NR2B subunits of N-methyl-D-aspartate receptor (NMDAR) or the voltage gated potassium channel of Drosophila (Eag) or any protein sequence which binds to the T-site of CaMKII similar to NR2B, conjugated to mitochondrial localizing signal sequence, or mutants of these sequences as described herein. Generation of mammalian expression constructs of ?-CaMKll as a chimera with green fluorescent protein (GFP-?-CaMKII) or its mutants as described herein.
    Type: Grant
    Filed: October 26, 2012
    Date of Patent: May 1, 2018
    Assignees: Rajiv Gandhi Centre for Biotechnology, Department of Biotechnology
    Inventors: Omkumar Vyomakesannair Ramakrishnapillai, Rajeev Kumar Raveendran, Mathew Steephan, Mayadevi Madhavan, Suma Priya Sudarsana Devi, Arunkumar Renganathan Chandrika, Archana Geetha Mohanan
  • Patent number: 9951132
    Abstract: The present invention provides antibodies that bind to prokineticin receptors (PROKRs) and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human PROKR1 and/or PROKR2. The present invention includes antibodies that bind cell surface-expressed PROKR1 and/or PROKR2. In certain embodiments, the antibodies of the present invention are capable of blocking prokineticin (PK)-mediated activation of one or more PROKR. The antibodies of the invention are useful for the treatment of various diseases and disorders mediated by prokineticin signaling.
    Type: Grant
    Filed: April 3, 2015
    Date of Patent: April 24, 2018
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Lynn Macdonald, Michael L. LaCroix-Fralish